Janus Henderson Group PLC Has $139.42 Million Holdings in Alexion Pharmaceuticals, Inc. (ALXN)

Janus Henderson Group PLC grew its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 1,697.6% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,145,918 shares of the biopharmaceutical company’s stock after acquiring an additional 1,082,171 shares during the quarter. Janus Henderson Group PLC owned 0.51% of Alexion Pharmaceuticals worth $139,424,000 at the end of the most recent quarter.

Other institutional investors also recently added to or reduced their stakes in the company. Guardian Life Insurance Co. of America boosted its holdings in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 6 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Alexion Pharmaceuticals in the first quarter worth $111,000. Fiduciary Trust Co. bought a new stake in Alexion Pharmaceuticals in the second quarter worth $111,000. Huntington National Bank boosted its holdings in Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 987 shares in the last quarter. Finally, Penserra Capital Management LLC boosted its holdings in Alexion Pharmaceuticals by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 144 shares in the last quarter. 94.25% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have commented on ALXN. SunTrust Banks, Inc. reissued a “buy” rating and issued a $165.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, July 14th. Leerink Swann reissued a “buy” rating and issued a $182.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. Zacks Investment Research downgraded Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. BidaskClub raised Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $138.00 target price on shares of Alexion Pharmaceuticals in a report on Wednesday, June 14th. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average price target of $154.56.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded down 0.65% during trading on Monday, hitting $140.38. The stock had a trading volume of 129,459 shares. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $149.34. The firm’s 50-day moving average price is $141.26 and its 200-day moving average price is $126.29. The company has a market cap of $31.33 billion, a price-to-earnings ratio of 60.88 and a beta of 1.39.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The company had revenue of $912.00 million during the quarter, compared to analyst estimates of $846.15 million. During the same period in the previous year, the business earned $1.13 EPS. Alexion Pharmaceuticals’s quarterly revenue was up 21.1% on a year-over-year basis. Analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.

In other Alexion Pharmaceuticals news, EVP Julie O’neill sold 11,160 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now directly owns 26,704 shares in the company, valued at approximately $3,738,560. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the sale, the director now owns 6,315 shares of the company’s stock, valued at $869,828.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,190 shares of company stock valued at $2,433,669. 4.35% of the stock is owned by company insiders.

WARNING: This article was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & in

Other institutional investors also recently added to or reduced their stakes in the company. Guardian Life Insurance Co. of America boosted its holdings in Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 6 shares in the last quarter. Meeder Asset Management Inc. bought a new stake in Alexion Pharmaceuticals in the first quarter worth $111,000. Fiduciary Trust Co. bought a new stake in Alexion Pharmaceuticals in the second quarter worth $111,000. Huntington National Bank boosted its holdings in Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock worth $131,000 after acquiring an additional 987 shares in the last quarter. Finally, Penserra Capital Management LLC boosted its holdings in Alexion Pharmaceuticals by 13.0% in the second quarter. Penserra Capital Management LLC now owns 1,248 shares of the biopharmaceutical company’s stock worth $151,000 after acquiring an additional 144 shares in the last quarter. 94.25% of the stock is currently owned by institutional investors and hedge funds.

Several research firms have commented on ALXN. SunTrust Banks, Inc. reissued a “buy” rating and issued a $165.00 target price on shares of Alexion Pharmaceuticals in a report on Friday, July 14th. Leerink Swann reissued a “buy” rating and issued a $182.00 target price on shares of Alexion Pharmaceuticals in a report on Monday, September 25th. Zacks Investment Research downgraded Alexion Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, October 2nd. BidaskClub raised Alexion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 5th. Finally, Morgan Stanley reissued an “overweight” rating and issued a $138.00 target price on shares of Alexion Pharmaceuticals in a report on Wednesday, June 14th. Six research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the stock. Alexion Pharmaceuticals has a consensus rating of “Buy” and an average price target of $154.56.

Alexion Pharmaceuticals, Inc. (NASDAQ ALXN) traded down 0.65% during trading on Monday, hitting $140.38. The stock had a trading volume of 129,459 shares. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $149.34. The firm’s 50-day moving average price is $141.26 and its 200-day moving average price is $126.29. The company has a market cap of $31.33 billion, a price-to-earnings ratio of 60.88 and a beta of 1.39.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $1.56 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a return on equity of 12.47% and a net margin of 15.31%. The company had revenue of $912.00 million during the quarter, compared to analyst estimates of $846.15 million. During the same period in the previous year, the business earned $1.13 EPS. Alexion Pharmaceuticals’s quarterly revenue was up 21.1% on a year-over-year basis. Analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.

In other Alexion Pharmaceuticals news, EVP Julie O’neill sold 11,160 shares of the business’s stock in a transaction that occurred on Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the completion of the sale, the executive vice president now directly owns 26,704 shares in the company, valued at approximately $3,738,560. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director Ann M. Veneman sold 700 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $137.74, for a total value of $96,418.00. Following the sale, the director now owns 6,315 shares of the company’s stock, valued at $869,828.10. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 17,190 shares of company stock valued at $2,433,669. 4.35% of the stock is owned by company insiders.

WARNING: This article was posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://ledgergazette.com/2017/10/09/janus-henderson-group-plc-has-139-42-million-holdings-in-alexion-pharmaceuticals-inc-alxn.html.

Alexion Pharmaceuticals Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply